UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 53

Sortiert nach

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.699-704

2020

Link zum Volltext

Verfügbarkeit prüfen

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.216-227

2017

Link zum Volltext

Verfügbarkeit prüfen

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Diabetes, obesity & metabolism, 2020-10, Vol.22 (10), p.1886-1891

2020

Link zum Volltext

Verfügbarkeit prüfen

Incretin hormones: Their role in health and disease

Diabetes, obesity & metabolism, 2018-02, Vol.20 (S1), p.5-21

2018

Link zum Volltext

Verfügbarkeit prüfen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Diabetes, obesity & metabolism, 2017-09, Vol.19 (9), p.1327-1328

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

Diabetes, obesity & metabolism, 2020-11, Vol.22 (11), p.2193-2198

2020

Link zum Volltext

Verfügbarkeit prüfen

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

Diabetes, obesity & metabolism, 2016-11, Vol.18 (11), p.1100-1109

2016

Link zum Volltext

Verfügbarkeit prüfen

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

Diabetes, obesity & metabolism, 2021-09, Vol.23 (S3), p.5-29

2021

Link zum Volltext

Verfügbarkeit prüfen

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2450-2458

2019

Link zum Volltext

Verfügbarkeit prüfen

Liraglutide and Glycaemic Outcomes in the LEADER Trial

Diabetes therapy, 2018-12, Vol.9 (6), p.2383-2392

2018

Link zum Volltext

Verfügbarkeit prüfen

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Diabetes, obesity & metabolism, 2017-03, Vol.19 (3), p.336-347

2017

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Diabetes, obesity & metabolism, 2020-06, Vol.22 (6), p.938-946

2020

Link zum Volltext

Verfügbarkeit prüfen

Meta‐analysis of head‐to‐head clinical trials comparing incretin‐based glucose‐lowering medications and basal insulin: An update including recently developed glucagon‐like peptide‐1 (GLP‐1) receptor agonists and the glucose‐dependent insulinotropic polypeptide/GLP‐1 receptor co‐agonist tirzepatide

Diabetes, obesity & metabolism, 2023-05, Vol.25 (5), p.1361-1371

2023

Link zum Volltext

Verfügbarkeit prüfen

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials

Diabetes, obesity & metabolism, 2020-09, Vol.22 (9), p.1537-1547

2020

Link zum Volltext

Verfügbarkeit prüfen

Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2017-02, Vol.19 (2), p.200-207

2017

Link zum Volltext

Verfügbarkeit prüfen

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Diabetes, obesity & metabolism, 2021-10, Vol.23 (10), p.2344-2353

2021

Link zum Volltext

Verfügbarkeit prüfen

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

Diabetes, obesity & metabolism, 2020-04, Vol.22 (4), p.599-611

2020

Link zum Volltext

Verfügbarkeit prüfen

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

Diabetes, obesity & metabolism, 2019-07, Vol.21 (7), p.1745-1751

2019

Link zum Volltext

Verfügbarkeit prüfen

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Diabetes, obesity & metabolism, 2022-05, Vol.24 (5), p.806-815

2022

Link zum Volltext

Verfügbarkeit prüfen

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial

Diabetes, obesity & metabolism, 2019-03, Vol.21 (3), p.525-532

2019

Link zum Volltext

Verfügbarkeit prüfen

Basal rate tests (24‐hour fasts) performed in type‐1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial

Diabetes, obesity & metabolism, 2017-06, Vol.19 (6), p.783-790

2017

Link zum Volltext

Verfügbarkeit prüfen

Glucagon-like peptide-1 in type 2 diabetes: the β-cell and beyond

Diabetes, obesity & metabolism, 2008-08, Vol.10 (s3), p.2-13

Nauck, Michael A

2008

Link zum Volltext

Verfügbarkeit prüfen

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

World journal of gastroenterology : WJG, 2006-03, Vol.12 (12), p.1874

2006

Link zum Volltext

Verfügbarkeit prüfen

The potential role of glucagon-like peptide 1 in diabetes

Current opinion in investigational drugs (London, England : 2000), 2004-04, Vol.5 (4), p.402

2004

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 53

Suche als RSS-Feed

Aktive Filter

Nur zeigenGeprüft (Peer-Review)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Mit Volltextzugriff
(41)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(25)
Science & Technology
(25)
Endocrinology & Metabolism
(23)
Humans
(21)
Diabetes
(20)
Diabetes Mellitus
(16)
Type 2 Diabetes
(16)
Diabetes Mellitus, Type 2 - Drug Therapy
(15)
Glucagon
(12)
Insulin
(11)
Female
(9)
Glucose
(9)
Male
(9)
Middle Aged
(9)
Endocrinology
(8)
Endocrinology, Diabetes And Metabolism
(8)
Internal Medicine
(8)
Liraglutide
(8)
Aged
(7)
Antidiabetics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

11 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and malignancies: a meta‐analysis based on cardiovascular outcomes trials

A meta‐analysis comparing clinical effects of short‐ or long‐acting GLP‐1 receptor agonists versus insulin treatment from head‐to‐head studies in type 2 diabetic patients

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists

Incretin hormones: Their role in health and disease

Incretin‐based glucose‐lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio‐vascular outcome trials

Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trials

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Liraglutide and Glycaemic Outcomes in the LEADER Trial

Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon‐like peptide‐1 receptor agonists: A systematic analysis of published clinical trials

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

Validation of distinct type 2 diabetes clusters and their association with diabetes complications in the DEVOTE, LEADER and SUSTAIN‐6 cardiovascular outcomes trials

Cardiovascular safety of oral semaglutide in patients with type 2 diabetes: Rationale, design and patient baseline characteristics for the PIONEER 6 trial

Addition of a dipeptidyl peptidase‐4 inhibitor, sitagliptin, to ongoing therapy with the glucagon‐like peptide‐1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes

Macronutrient intake, appetite, food preferences and exocrine pancreas function after treatment with short‐ and long‐acting glucagon‐like peptide‐1 receptor agonists in type 2 diabetes

Effects of sequential treatment with lixisenatide, insulin glargine, or their combination on meal‐related glycaemic excursions, insulin and glucagon secretion, and gastric emptying in patients with type 2 diabetes

Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trials

Acute effects of linagliptin on intact and total glucagon‐like peptide‐1 and gastric inhibitory polypeptide levels in insulin‐dependent type 2 diabetes patients with and without moderate renal impairment

Health‐related quality of life in people with type 2 diabetes participating in the LEADER trial

Basal rate tests (24‐hour fasts) performed in type‐1 diabetic subjects with either absolute fasting or snacks containing negligible carbohydrate amounts result in similar glucose profiles: A randomized controlled prospective trial

Glucagon-like peptide-1 in type 2 diabetes: the β-cell and beyond

Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls

The potential role of glucagon-like peptide 1 in diabetes

Aktive Filter

Suchergebnisse filtern